Skip to content
AASLD Family of Websites: Liver Fellow Network
AASLD.org AASLD Foundation LiverLearning Career Center Journals The Liver Meeting HCV Guidelines
AASLD Logo
AASLD Logo

LFN Main Navigation

  • Topics
    Acute Liver Failure Alcohol-Associated Liver Disease Autoimmune Hepatitis Career Development and Mentorship Cholestatic Liver Disease Complications of Liver Disease and Portal Hypertension Drug-Induced Liver Disease HepMadness Inherited Disorders Liver Anatomy, Development, and Physiology Liver Infections Liver Physiology Liver Related Infections MASLD/MASH Neoplasms of the Liver Pathology Pediatrics Pregnancy-Related Liver Disease Symptoms and Clinical Presentation of Liver Disease and Portal HTN Systemic Conditions with Hepatic Manifestations Transplantation and Surgery Vascular Viral Hepatitis
  • Core Series
    Back to Basics Clinical Pearls Webinars Evidence Corner Pathology Pearls Liver Talks Podcasts Tools of the Trade View All Core Series Guidelines Practice Questions Video Tutorials The Why? Series
  • Tweetorials
  • About
  • Core Series
  • Evidence Corner
  • Pushing The Limits In HCC: Advancing Transplantation Strategies And Survival Outcomes

Pushing the limits in HCC: Advancing Transplantation Strategies and Survival Outcomes

October 16, 2024

Ahmed El Sabagh

Share

Copy Link Twitter Facebook
  1. Improved recurrence-free survival in patients with HCC with post-transplant plasma exchange
  2. AFP-L3 and DCP are superior to AFP in predicting waitlist dropout in HCC patients: Results of a prospective study
  3. Neoadjuvant programmed cell death 1 inhibitor before liver transplantation for HCC is not associated with increased graft loss
  4. Development and validation of a REcurrent Liver cAncer Prediction ScorE (RELAPSE) following liver transplantation in patients with hepatocellular carcinoma: Analysis of the US Multicenter HCC Transplant Consortium
  5. Outcomes in liver transplant recipients with nonalcoholic fatty liver disease-related HCC: results from the US multicenter HCC transplant consortium
HepMadness

Share

Copy Link Twitter Facebook

Written By:

Ahmed El Sabagh

IM Resident, Medstar Georgetown

Related Content

HepMadness

October 15, 2025

Pediatric Immunosuppression

October 14, 2025

Rethinking Alcohol-Associated Hepatitis Practice

October 14, 2025

AASLD LFN Logo

Follow Us

Disclaimer & Privacy Policy

© 2026 copyright